Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 4/20 | 0.55 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.53 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.53 |
| ▸ | CNR1 | P21554 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL91535 | 0.86 | MAPT (0.51) | FPR2ROCK2ROCK1CNR1LMNA | |
| SCHEMBL91393 | 0.86 | ROCK2 (0.64) | ROCK2ROCK1CNR1LMNASMN1; SMN2 | |
| SCHEMBL77071 | 0.83 | KMT2A (0.69) | FPR2ROCK2ROCK1CNR1SMN1; SMN2 | |
| SCHEMBL2559922 | 0.81 | ROCK1 (0.80) | ROCK2ROCK1KMT2AMAPTMAPK1 | |
| SCHEMBL91380 | 0.81 | TRPV1 (0.48) | ROCK2ROCK1CNR1LMNASMN1; SMN2 | |
| SCHEMBL10081817 | 0.79 | TP53 (0.54) | LMNASMN1; SMN2KMT2ARAB9AMAPT | |
| SCHEMBL91525 | 0.79 | LMNA (0.70) | ROCK2ROCK1LMNASMN1; SMN2KMT2A | |
| SCHEMBL10082863 | 0.78 | FPR2 (0.59) | FPR2ROCK2ROCK1CNR1LMNA | |
| SCHEMBL91577 | 0.78 | CNR1 (0.56) | ROCK2ROCK1CNR1LMNASMN1; SMN2 | |
| SCHEMBL91529 | 0.78 | ROCK1 (0.70) | ROCK2ROCK1LMNAKMT2ARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129415-B2 | Fungicide hydroximoyl-tetrazole derivatives | BAYER CROPSCIENCE AG (DE) | 2012-03-06 | — | — | US | disclosed |
| US-20090192196-A1 | Fungicide hydroximoyl-tetrazole derivatives | BAYER CROPSCIENCE AG (DE) | 2009-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192196-A1 | Fungicide hydroximoyl-tetrazole derivatives | HAAO, HAO1, CYP51A1 | FPR2 3656/4885ROCK2 2794/4885ROCK1 2709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.